PulmoBioMed, a breath sampling technology company based in Newcastle Upon Tyne, UK, has successfully raised £1.4 million in funding. The funding round was led by North East Venture Fund, managed by Mercia Ventures, and included investment from Northumbria University, SFC Capital, and private investors from the USA, EU, and UK. In addition to this funding, PulmoBioMed also secured a £700K grant from Innovate UK. The company plans to use these funds to develop a manufacturing process, scale up production, and register their product in the US. They also intend to relocate from the university to new premises in Newcastle city centre, creating seven new jobs in the process.
CEO and Founder Sterghios Moschos leads PulmoBioMed, which offers a non-invasive breath sampling technology solution.
Their handheld device, known as PBM-HALE, captures breath samples from patients as they exhale. The device is capable of separating large aerosol droplets from the mouth from smaller droplets from the deep lung, ensuring uncontaminated deep lung samples for analysis. Clinical studies have demonstrated that the device can detect and quantify lung infections and inflammation in 100% of symptomatic cases in just two minutes.
Sterghios Moschos commented on the funding news, highlighting the importance of PulmoBioMed's technology in the field of respiratory care. He stated, "PulmoBioMed was founded during the pandemic to address the need for reliable breath-based diagnostics. By enabling quick and non-invasive deep lung sampling, our technology has the potential to transform respiratory care, benefiting the over 300 million asthma patients who suffer from slow diagnosis and the millions of others who are hospitalized every year with undiagnosable pneumonias."